ATE444757T1 - Verwendung der p2x7 antagonisten o-atp oder bbg zur behandlung von der neurodegerative phases des multiple sklerosis - Google Patents
Verwendung der p2x7 antagonisten o-atp oder bbg zur behandlung von der neurodegerative phases des multiple sklerosisInfo
- Publication number
- ATE444757T1 ATE444757T1 AT04766900T AT04766900T ATE444757T1 AT E444757 T1 ATE444757 T1 AT E444757T1 AT 04766900 T AT04766900 T AT 04766900T AT 04766900 T AT04766900 T AT 04766900T AT E444757 T1 ATE444757 T1 AT E444757T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- multiple sclerosis
- neurodegerative
- bbg
- atp
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 102000000033 Purinergic Receptors Human genes 0.000 abstract 1
- 108010080192 Purinergic Receptors Proteins 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301853A ES2223287B1 (es) | 2003-08-04 | 2003-08-04 | Compuestos para el tratamiento de enfermedades desmielinizantes y autoinmunes. |
| PCT/ES2004/000361 WO2005014007A1 (es) | 2003-08-04 | 2004-08-04 | Compuestos para el tratamiento de enfermedades desmielinizantes y autoinmunes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE444757T1 true ATE444757T1 (de) | 2009-10-15 |
Family
ID=34130551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04766900T ATE444757T1 (de) | 2003-08-04 | 2004-08-04 | Verwendung der p2x7 antagonisten o-atp oder bbg zur behandlung von der neurodegerative phases des multiple sklerosis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070099863A1 (de) |
| EP (1) | EP1655032B1 (de) |
| AT (1) | ATE444757T1 (de) |
| CA (1) | CA2534868A1 (de) |
| DE (1) | DE602004023517D1 (de) |
| ES (2) | ES2223287B1 (de) |
| PL (1) | PL1655032T3 (de) |
| PT (1) | PT1655032E (de) |
| WO (1) | WO2005014007A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2717166A1 (en) * | 2008-03-03 | 2009-09-19 | Converge Biotech Inc. | Methods of modulating t cell-dependent immune responses |
| ES2338970B1 (es) * | 2008-07-31 | 2011-03-11 | Universidad Complutense De Madrid | Uso de antagonistas del receptor p2x7 para favorecer el crecimiento yramificacion axonales. |
| US20110166223A1 (en) * | 2008-08-19 | 2011-07-07 | Cedars-Sinai Medical Center | Methods of inhibiting fgfr3 signaling |
| ITTO20080759A1 (it) * | 2008-10-15 | 2010-04-16 | Medestea Res & Production S R L | Impiego di oatp come farmaco immunodepressivo |
| WO2013082565A1 (en) * | 2011-12-02 | 2013-06-06 | Michael Kaleko | Therapies for disorders of the cornea and conjunctiva |
| CN103301462B (zh) * | 2012-03-09 | 2015-06-03 | 海南康芝药业股份有限公司 | 治疗病毒疾病的成分和方法 |
| WO2017070660A1 (en) * | 2015-10-23 | 2017-04-27 | Baylor College Of Medicine | Targeting p2 purinergic receptors to treat hepatocellular carcinoma (hcc) |
| US10624866B2 (en) * | 2018-03-05 | 2020-04-21 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Composition for prevention or treatment of chronic pain comprising Evans blue |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589458A (en) * | 1992-11-13 | 1996-12-31 | Thomas Jefferson University | Compounds that inhibit T cell proliferation and methods for using the same |
| GB9615202D0 (en) * | 1996-07-19 | 1996-09-04 | Smithkline Beecham Plc | Pharmaceuticals |
| US6117445A (en) * | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| WO2003103675A2 (en) * | 2002-06-06 | 2003-12-18 | Endacea, Inc. | Combination treatments for purinoceptor-related disorders |
-
2003
- 2003-08-04 ES ES200301853A patent/ES2223287B1/es not_active Expired - Fee Related
-
2004
- 2004-08-04 AT AT04766900T patent/ATE444757T1/de not_active IP Right Cessation
- 2004-08-04 EP EP04766900A patent/EP1655032B1/de not_active Expired - Lifetime
- 2004-08-04 WO PCT/ES2004/000361 patent/WO2005014007A1/es active Search and Examination
- 2004-08-04 ES ES04766900T patent/ES2334505T3/es not_active Expired - Lifetime
- 2004-08-04 CA CA002534868A patent/CA2534868A1/en not_active Abandoned
- 2004-08-04 PT PT04766900T patent/PT1655032E/pt unknown
- 2004-08-04 DE DE602004023517T patent/DE602004023517D1/de not_active Expired - Lifetime
- 2004-08-04 US US10/567,238 patent/US20070099863A1/en not_active Abandoned
- 2004-08-04 PL PL04766900T patent/PL1655032T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2223287A1 (es) | 2005-02-16 |
| WO2005014007B1 (es) | 2005-03-31 |
| DE602004023517D1 (de) | 2009-11-19 |
| EP1655032A1 (de) | 2006-05-10 |
| EP1655032B1 (de) | 2009-10-07 |
| PT1655032E (pt) | 2010-01-07 |
| ES2334505T3 (es) | 2010-03-11 |
| WO2005014007A1 (es) | 2005-02-17 |
| ES2223287B1 (es) | 2006-04-16 |
| CA2534868A1 (en) | 2005-02-17 |
| US20070099863A1 (en) | 2007-05-03 |
| PL1655032T3 (pl) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| CY1113306T1 (el) | Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6 | |
| NZ617196A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
| CY1115012T1 (el) | Μεθοδος συστηματικης εξετασης παρασκευασματων παρασιτου για αποτελεσματικοτητα στην αποτροπη και ελεγχο ασθενειων | |
| CL2004000827A1 (es) | Compuestos derivados de 1,2-diazoles o 1,3-diazoles condensados con un heterociclo, composicion farmaceutica; y uso para tratar enfermedades moduladas por antagonistas de receptores canabinoides, tales como obesidad y sobrepeso. | |
| ATE466085T1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| CY1112505T1 (el) | Ανοσοκατασταλτικες ενωσεις και συνθεσεις | |
| NO20055211L (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| ES2128735T3 (es) | Composiciones farmaceuticas que comprenden un antagonista de opiaceos y de sales de calcio y su uso para el tratamiento de patologias en las que intervienen las endorfinas. | |
| EA200970342A1 (ru) | Антагонисты рецептора глюкагона, композиции, содержащие такие соединения, и способы применения | |
| BRPI0518281A2 (pt) | inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos | |
| BRPI0606740A2 (pt) | compostos de bis arila e heteroarila substituìdas como antagonistas de 5ht2a seletivos | |
| NO20065534L (no) | Ureaantagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander. | |
| CY1105748T1 (el) | Χρηση της ριλουζολης συνδυασμενης με καταλληλα εκδοχα και προσθετες ουσιες για τη θεραπεια ασθενειων που χαρακτηριζονται απο υπερβολικο πολλαπλασιασμο των κερατινοκυτταρων ιδιαιτερως της νευροδερματιτιδας και της ψωριασης | |
| AR052056A1 (es) | Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo | |
| HRP20050585A2 (en) | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | |
| ATE444757T1 (de) | Verwendung der p2x7 antagonisten o-atp oder bbg zur behandlung von der neurodegerative phases des multiple sklerosis | |
| PA8583601A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| CY1110711T1 (el) | Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3 | |
| ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
| BRPI0519646A2 (pt) | composição, processo para preparar uma composição de ração para felino baseada em carne e carboidrato, produto, método para prevenir ou tratar diabetes em um felino suscetìvel a ou sofrendo de diabetes, kit adequado para prevenir ou tratar diabetes, meio, uso de uma composição, e, processo para preparar uma composição baseada em carne e carboidrato para consumo por um felino | |
| ATE551057T1 (de) | Zusammensetzungen von pirfenidon/toll-like rezeptor (tlr)-antagonisten und verfahren zu ihrer verwendung zur stimulierung der produktion des granulozyten-kolonie-stimulierenden faktors (g-csf) | |
| ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
| EA200600996A1 (ru) | Композиция для полезного воздействия на кожу с использованием ключевых промежуточных продуктов клеточного метаболизма | |
| DE60315842D1 (de) | Verwendung von hesperidin oder einem seiner derivate zur herstellung eines medikaments für die stimulierung der knochenbildung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |